Fine-Tuning Cancer Immunotherapy: Optimizing the Gut Microbiome
- PMID: 27474734
- DOI: 10.1158/0008-5472.CAN-16-0448
Fine-Tuning Cancer Immunotherapy: Optimizing the Gut Microbiome
Abstract
The equilibrium linking the intestinal microbiota, the intestinal epithelium, and the host immune system establishes host health and homeostasis, with perturbations of this balance resulting in chronic inflammatory and autoimmune immunopathologies. The mutualistic symbiosis between gut microbiota and host immunity raises the possibility that dysbiosis of the intestinal content also influences the outcome of cancer immunotherapy. Here, we present our recent findings that specific gut-resident bacteria determine the immunotherapeutic responses associated with CTLA-4 checkpoint blockade. This new evidence hints that interindividual differences in the microbiome may account for the significant heterogeneity in therapeutic and immunopathologic responses to immune checkpoint therapies. We discuss how this new understanding could improve the therapeutic coverage of immune checkpoint inhibitors, and potentially limit their immune-mediated toxicity, through the use of adjunctive "oncomicrobiotics" that indirectly promote beneficial immune responses through optimizing the gut microbiome. Cancer Res; 76(16); 4602-7. ©2016 AACR.
©2016 American Association for Cancer Research.
Similar articles
-
Modulatory effects of gut microbiome in cancer immunotherapy: A novel paradigm for blockade of immune checkpoint inhibitors.Cancer Med. 2021 Feb;10(3):1141-1154. doi: 10.1002/cam4.3694. Epub 2020 Dec 25. Cancer Med. 2021. PMID: 33369247 Free PMC article. Review.
-
Gut microbiome and cancer immunotherapy.Cancer Lett. 2019 Apr 10;447:41-47. doi: 10.1016/j.canlet.2019.01.015. Epub 2019 Jan 23. Cancer Lett. 2019. PMID: 30684593 Review.
-
Modulation of cancer immunotherapy efficacy by gut microbiota.Discov Med. 2019 Feb;27(147):93-100. Discov Med. 2019. PMID: 30939293
-
Manipulating Gut Microbiota Composition to Enhance the Therapeutic Effect of Cancer Immunotherapy.Integr Cancer Ther. 2019 Jan-Dec;18:1534735419876351. doi: 10.1177/1534735419876351. Integr Cancer Ther. 2019. PMID: 31517538 Free PMC article. Review.
-
Cancer and the Microbiome-Influence of the Commensal Microbiota on Cancer, Immune Responses, and Immunotherapy.Gastroenterology. 2021 Jan;160(2):600-613. doi: 10.1053/j.gastro.2020.11.041. Epub 2020 Nov 28. Gastroenterology. 2021. PMID: 33253684 Free PMC article. Review.
Cited by
-
Pharmacomicrobiomics in precision cancer therapy: bench to bedside.Front Immunol. 2024 Sep 9;15:1428420. doi: 10.3389/fimmu.2024.1428420. eCollection 2024. Front Immunol. 2024. PMID: 39315107 Free PMC article. Review.
-
Impact of antibiotics, corticosteroids, and microbiota on immunotherapy efficacy in patients with non-small cell lung cancer.Heliyon. 2024 Jul 1;10(13):e33684. doi: 10.1016/j.heliyon.2024.e33684. eCollection 2024 Jul 15. Heliyon. 2024. PMID: 39050456 Free PMC article.
-
Gut microbes as medical signature for the effectiveness of immunotherapy in patients with advanced non-small cell lung cancer.Aging Med (Milton). 2024 Feb 22;7(1):121-130. doi: 10.1002/agm2.12292. eCollection 2024 Feb. Aging Med (Milton). 2024. PMID: 38571678 Free PMC article. Review.
-
Uncovering the flip side of immune checkpoint inhibitors: a comprehensive review of immune-related adverse events and predictive biomarkers.Int J Biol Sci. 2024 Jan 1;20(2):621-642. doi: 10.7150/ijbs.89376. eCollection 2024. Int J Biol Sci. 2024. PMID: 38169638 Free PMC article. Review.
-
Focus on Immune Checkpoint Inhibitors-related Intestinal Inflammation: From Pathogenesis to Therapeutical Approach.Inflamm Bowel Dis. 2024 Jun 3;30(6):1018-1031. doi: 10.1093/ibd/izad229. Inflamm Bowel Dis. 2024. PMID: 37801695 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
